Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals (Nasdaq: XENE) has announced it will report its third quarter 2024 financial results after U.S. market close on Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day. Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference on October 7, 2024. The company will present a fireside chat at 11:40 am Eastern Time, with a live webcast available on Xenon's website.
Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their novel product pipeline focuses on areas of high unmet medical need, including epilepsy and depression. The company's lead product, azetukalner, is a Kv7 channel opener in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator.
Xenon Pharmaceuticals (Nasdaq:XENE) presented three posters at the 15th European Epilepsy Congress showcasing long-term data for azetukalner, a novel Kv7 channel opener, in treating focal onset seizures (FOS). Key highlights include:
1. Patients in the X-TOLE open-label extension study showed >90% reduction in median monthly seizure frequency after 30 months.
2. Approximately 25% of patients on azetukalner for ≥2 years experienced ≥1 year of seizure freedom.
3. Quality of life improvements were reported in adults with FOS treated with azetukalner.
4. Xenon is conducting three Phase 3 trials for azetukalner in FOS and primary generalized tonic-clonic seizures (PGTCS).
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has appointed Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the senior executive team. Dr. Ronsheim, with 25 years of experience in pharmaceutical development and manufacturing, will lead Chemistry, Manufacturing and Controls (CMC), Program Management, and Quality Assurance. He will focus on preparing for the commercial launch of azetukalner, Xenon's lead Kv7 channel opener in late-stage clinical development for epilepsy and depression.
Dr. Ronsheim joins Xenon from Innoviva Specialty Therapeutics, where he served as President. His extensive experience includes leadership roles at Entasis Therapeutics, Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals, and Forest Laboratories. His appointment comes at a important time as Xenon advances its Phase 3 epilepsy and MDD programs and progresses its pre-clinical assets.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Q2 2024 financial results, highlighting multiple clinical advancements and financial figures.
The phase 3 epilepsy program with azetukalner continues, anticipating topline data for X-TOLE2 in H2 2025. The MDD program is on track, with a Phase 3 study expected to initiate in H2 2024. Xenon is also progressing multiple Kv7 and Nav1.7 candidates, with IND filings expected in 2025.
Financially, the company reported cash and equivalents of $850.6 million as of June 30, 2024, down from $930.9 million at the end of 2023. Research and development expenses increased to $49.7 million, with a net loss of $57.9 million for Q2 2024, compared to a $47.5 million loss in Q2 2023.
Xenon remains financially poised to operate into 2027, bolstered by ongoing clinical trials and a robust pipeline of innovative treatments.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the results.
Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their lead product, Azetukalner, a Kv7 channel opener, is in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator in its class.
Xenon Pharmaceuticals (Nasdaq:XENE) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 10-13, 2024, in Miami, FL.
Key executives, Ian Mortimer, President and CEO, and Chris Von Seggern, Chief Commercial Officer, will present during a fireside chat on June 12, at 4:00 pm ET. The presentation will be webcast live and available for replay on Xenon's investor relations webpage.
Xenon focuses on developing innovative treatments for neurological and psychiatric disorders, with a product pipeline addressing unmet medical needs such as epilepsy and depression.
Xenon Pharmaceuticals has presented Phase 2 clinical data for azetukalner (XEN1101) in major depressive disorder (MDD) at the ASCP 2024 Annual Meeting.
Key findings include a meaningful reduction in depression and early onset of action, with a significant reduction in anhedonia. Though a 3.04 MADRS score difference between placebo and 20 mg azetukalner was observed, it was not statistically significant (P=0.135). Significant differences were noted in HAM-D17 (P=0.042) and SHAPS scores (P=0.046).
Azetukalner was well tolerated with no serious adverse events reported. Common TEAEs included dizziness (17.9%), somnolence (10.7%), headache (8.9%), and disturbance in attention (8.9%). Discontinuation rates were low.
The company aims to initiate Phase 3 trials in late 2024.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) reported financial results for Q1 2024 and provided a corporate update. The company received approval for the use of 'azetukalner' as the nonproprietary name for XEN1101. Progress continues in the epilepsy program, with Phase 3 expected to start in MDD in the second half of 2024. Financially, Xenon has cash to fund operations into 2027.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the BofA Securities Health Care Conference 2024. The presentation will take place on May 15, 2024, in Las Vegas, NV, featuring the company's President, CEO, and CFO. The webcast will be available on the company's website for replay. Xenon is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for neurological and psychiatric disorders, such as epilepsy and depression.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
